Acosta EP - Search Results

1

Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1.

Chandasana H, van Dijkman SC, Mehta R, Bush M, Rabie H, Flynn P, Cressey TR, Acosta EP, Brooks KM; IMPAACT 2019 Study Team. Chandasana H, et al. Among authors: acosta ep. Infect Dis Ther. 2024 Aug;13(8):1877-1891. doi: 10.1007/s40121-024-01008-y. Epub 2024 Jul 4. Infect Dis Ther. 2024. PMID: 38961048 Free PMC article.

2

Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.

Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R; IMPAACT P1093, ODYSSEY (PENTA 20) Study Teams. Chandasana H, et al. Among authors: acosta ep. Clin Pharmacokinet. 2023 Oct;62(10):1445-1459. doi: 10.1007/s40262-023-01289-5. Epub 2023 Aug 21. Clin Pharmacokinet. 2023. PMID: 37603217 Free PMC article.

3

Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatrics.

Chandasana H, Hayes S, Buchanan AM, Brothers C, Wiznia A, Bartlett M, Popson S, Townley E, George K, Vavro C, Ruel T, Acosta EP, Singh R; IMPAACT P1093 Team. Chandasana H, et al. Among authors: acosta ep. AIDS. 2024 Jul 15;38(9):F11-F18. doi: 10.1097/QAD.0000000000003929. Epub 2024 May 17. AIDS. 2024. PMID: 38768443

4

Impact of Genetic Variants in ABCG2 , NR1I2 , and UGT1A1 on the Pharmacokinetics of Dolutegravir in Children.

Spector SA, Brummel SS, Chang A, Wiznia A, Ruel TD, Acosta EP; for IMPAACT P1093 Team. Spector SA, et al. Among authors: acosta ep. J Acquir Immune Defic Syndr. 2024 Mar 1;95(3):297-303. doi: 10.1097/QAI.0000000000003358. J Acquir Immune Defic Syndr. 2024. PMID: 38180896

5

Pilot and feasibility study of dietary composition with elexacaftor-tezacaftor-ivacaftor concentrations in people with cystic fibrosis.

Rose NR, Bailey J, Anderson JD, Chalamalla AR, Ryan KJ, Acosta EP, Guimbellot JS. Rose NR, et al. Among authors: acosta ep. Pharmacotherapy. 2024 Dec;44(12):920-926. doi: 10.1002/phar.4630. Epub 2024 Dec 23. Pharmacotherapy. 2024. PMID: 39716404

6

Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance.

Bollar GE, Shaffer KM, Keith JD, Oden AM, Dowell AE, Ryan KJ, Acosta EP, Guimbellot JS, Kiedrowski MR, Birket SE. Bollar GE, et al. Among authors: acosta ep. JAC Antimicrob Resist. 2024 Nov 20;6(6):dlae185. doi: 10.1093/jacamr/dlae185. eCollection 2024 Dec. JAC Antimicrob Resist. 2024. PMID: 39659642 Free PMC article.

7

Ivacaftor for Chronic Obstructive Pulmonary Disease - Results from a Phase 2, Randomized Controlled Trial.

Vijaykumar K, Solomon GM, Guimbellot J, Acosta EP, Bhambhavni PG, White S, Kim H, Raju SV, Rasmussen LW, Harris N, Liu B, Hathorne H, Rowe SM, Dransfield MT. Vijaykumar K, et al. Among authors: acosta ep. Am J Respir Crit Care Med. 2024 Sep 24. doi: 10.1164/rccm.202407-1302OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39316773

8

Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia.

Liu Z, Anderson JD, Rose NR, Baker EH, Dowell AE, Ryan KJ, Acosta EP, Guimbellot JS. Liu Z, et al. Among authors: acosta ep. Pulm Pharmacol Ther. 2024 Sep;86:102314. doi: 10.1016/j.pupt.2024.102314. Epub 2024 Jul 2. Pulm Pharmacol Ther. 2024. PMID: 38964603

9

Pharmacokinetic variability of CFTR modulators from standard and alternative regimens.

Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS. Rose NR, et al. Among authors: acosta ep. Pulm Pharmacol Ther. 2024 Sep;86:102301. doi: 10.1016/j.pupt.2024.102301. Epub 2024 May 24. Pulm Pharmacol Ther. 2024. PMID: 38797221

10

Hemopexin reverses activation of lung eIF2α and decreases mitochondrial injury in chlorine-exposed mice.

Matalon S, Yu Z, Dubey S, Ahmad I, Stephens EM, Alishlash AS, Meyers A, Cossar D, Stewart D, Acosta EP, Kojima K, Jilling T, Mobley JA. Matalon S, et al. Among authors: acosta ep. Am J Physiol Lung Cell Mol Physiol. 2024 Apr 1;326(4):L440-L457. doi: 10.1152/ajplung.00273.2023. Epub 2023 Dec 27. Am J Physiol Lung Cell Mol Physiol. 2024. PMID: 38150547

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

211 results

Search Page

Filters